Clinicogenomics & Patient Agency Series
Disparities remain for the equitable distribution of benefits afforded by advances in precision medicine and related technologies. Genomic medicine presents a unique social bargain in that people benefit from genomic medicine only when they contribute their genetic data to data commons. As a result, artificial intelligence (AI) models using these data are constrained by bias and blind spots and expanded use of AI will amplify existing disparities. Current data governance practices do not adequately balance agency of patients and institutional stewards over data, so trust is essential, but continues to be a barrier. The provenance of clinical data as intellectual property also vexes patients, institutions, researchers, and other data stewards on the healthcare ecosystem. Digital tools provide some solutions.
Purpose
Data Collaboration in the Texas Medical Center: Opportunities and challenges for TMC3
Disparities remain for the equitable distribution of benefits afforded by advances in precision medicine and related technologies. Genomic medicine presents a unique social bargain in that people benefit from genomic medicine only when they contribute their genetic data to data commons. As a result, artificial intelligence (AI) models using these data are constrained by bias and blind spots and expanded use of AI will amplify existing disparities. Current data governance practices do not adequately balance agency of patients and institutional stewards over data, so trust is essential, but continues to be a barrier. The provenance of clinical data as intellectual property also vexes patients, institutions, researchers, and other data stewards on the healthcare ecosystem. Digital tools provide some solutions.
Program
12:30 p.m.-1:00 p.m. |
Check-in and networking |
1:00-1:30 p.m. |
Amber Hartley, Chief Business Officer Enabling health research networks through longitudinal data governance and knewledge graphs |
1:30-2:00 p.m. |
30 Minute discussion |
2:00-2:30 p.m. |
Nate Ranes, Head of Healthcare & Life Sciences Population scale clinicogenomic data networks through federated governance and consesus data models |
2:30-3:00 p.m. |
30 Minute discussion |
3:00-3:15 p.m. |
BREAK |
3:15-3:45 p.m. |
Dr. Qi Li, Physician Executive InterSystems Real world examples of capturing clinical genomics data in EHR to support patient care and research. |
3:45-4:15 p.m. | 30 Minute discussion |
4:15-4:45 p.m. |
Dr. Rick Silva, Executive Director Clinical, Translation, and Industry Collaborations Bringing Data Stewards Together at Texas A&M to Address the Multiagent Challenges in Clinicogenomics and Biobanking |
4:45-5:15 p.m. | 30 Minute discussion |
Speakers
Panel
Nate Raine - Head of Healthcare & Life Sciences Lifebit
Nate Raine is the Head at Lifebit for the Federal Health, Health Nonprofit, and Life Sciences sectors, bringing over a decade of specialized expertise in crafting and executing strategies tailored for these complex and dynamic fields. At Lifebit, Nate is a key figure in driving strategic initiatives, particularly in the Life Sciences sector, where his proficiency in enterprise strategy and operational optimization stands out.
Nate excels in strategic design, stakeholder engagement, and fine-tuning business operations, with a strong focus on leveraging data insights to guide decision-making and shape future strategies. His work is consistently recognized for its impact on governance and sustainable growth within the Life Sciences and healthcare ecosystems.
In addition to his strategic role, Nate is committed to developing the next generation of professionals at Lifebit. He is actively engaged in business development, where he has made significant contributions by cultivating and maintaining critical partnerships within the Healthcare, Life Sciences, and Global Healthcare ecosystems. His work ensures that Lifebit remains at the forefront of innovation and collaboration in these industries.
Qi Li PhD - InterSystems
Qi Li, M.D. is physician executive at InterSystems and lead several innovation efforts for product development and business strategy. Dr. Li has held various product leadership roles at Harris Healthcare, Partners Healthcare, and several startup companies in healthcare IT.
Rick Silva PhD, Texas A&M Health
Dr. Rick Silva joined the Texas A&M in 2019 to develop an external-facing collaborations program to augment the clinical and economic impact of the research enterprise at the Texas A&M Health Sciences Center. He has successfully led over 300 transactions with academic, nonprofit, and commercial organizations in the US, Europe, and Asia, ranging from start-ups to Fortune 500® companies including the creation of 60 biomedical startup companies.
Prior to Texas A&M, he spent 5 years at University of Arizona’s academic medical center in a similar role spanning the implementation of Banner Health’s academic affiliation with University of Arizona and assuming operation of their hospitals and practice plan. Previously, in 15 years at the University of Colorado, he had diverse roles in developing and leading a variety of collaborations including licensing transactions, technology development partnerships, public-private partnerships, multiparty collaborations, clinical trials, biomarker validation projects, supply and distribution agreements, strategic alliances, and a major emphasis on new venture development.
He holds an academic appointment in Texas A&M’s Institute for Biosciences and Technology in the Texas Medical Center where he has led implementation of a pharmacogenomic clinical practice and registry that utilizes several artificial intelligence technologies for clinical decision support. He publishes and speaks on emergent collaboration models at the academic industry interface.
Dr. Silva is passionate about strategies for achieving organizational effectiveness at the academic medical center- industry interface.
He received a Bachelor of Science degree in Agriculture from New Mexico State University, a Doctor of Philosophy in Physiology from Colorado State University, and a Master of Business Administration emphasizing Entrepreneurship and Finance from the University of Colorado-Boulder Leeds School of Business and is Certified Licensing Professional.
Amber Hartley - Chief Strategy Officer - BurstIQ
Amber Hartley is the Chief Strategy Officer for BurstIQ, a Denver-based blockchain company that operates the LifeGraph®, an advanced data management platform that harnesses the trust and security of Web3 and blockchain to conquer data chaos and power future-ready AI solutions. Prior to joining BurstIQ, Amber ran the national innovation center at Catholic Health Initiatives and has been leading partnerships for almost 25 years at various biotechnology, high tech, and healthcare companies. She holds a B.S. in Animal Physiology & Neuroscience and a master’s degree in biotechnology.
Registration
Registration is free but required
A block of rooms has been reserved for the event please use this link to take advantage of the reserve block: Click Here
September 20, 2024
Herman Hall at TMC3
Parking is available in the Collaborative Building Garage, accessed from Lehall Street.
Parking validations will be available at registration.